Skip to main content


Featured Article
According to a recent announcement, Roche has won a reprieve from an expected wave of cheaper versions of its biotech cancer drugs as US regulators knocked back a biosimilar form of rituximab made by…
During his presentation at the AMCP 2018 Annual Meeting, “2017-2018 Pharmaceutical Marketplace Trends,” Douglas Long, BS, MBA, Vice President, Industry Relations at IQVIA, outlined the market trends…


In this blog, Russel J Spjut, owner of Formulary Intel Consulting, discusses how biosimilars have delivered a false hope of price reductions comparable to generic drugs.
Back to Top